Essex Investment Management’s Biolase, Inc. BIOL Stock Holding History

Essex Investment Management’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Hold	0	–	–	–	420
2023 Q1	–	Hold	0	–	–	–	428
2022 Q4	–	Sell	-1,053	Closed	-$152K	–	437
2022 Q3	$256K	Buy	1,053 +404	+62%	+$161K	0.04%	266
2022 Q2	$297K	Hold	649	–	–	0.05%	266
2022 Q1	$573K	Buy	649 +16	+3%	+$14.8K	0.07%	258
2021 Q4	$617K	Buy	633 +313	+98%	+$395K	0.07%	259
2021 Q3	$511K	Buy	+320	New	+$522K	0.06%	270
2015 Q2	–	Sell	-2	Closed	-$42K	–	342
2015 Q1	$42K	Hold	2	–	–	0.01%	307
2014 Q4	$63K	Hold	2	–	–	0.01%	317
2014 Q3	$66K	Buy	+2	New	+$56.6K	0.01%	342

Other funds holding BIOL

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

APP

Avantax Planning Partners Dubuque, Iowa $4.02B AUM 20% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Zhang Financial Portage, Michigan $3.42B AUM 23.04% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Essex Investment Management's BIOL Position: Q2 2023 in Review

Essex Investment Management held its Biolase, Inc. (BIOL) position steady in Q2 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #420.

Essex Investment Management first reported a position in BIOL in Q3 2014 and has held it in 8 quarters since. The position peaked at $617K in Q4 2021. 25 funds tracked by Wall St. Rank hold BIOL as of Q2 2023.

Essex Investment Management held 0 shares of Biolase, Inc. worth $0 as of Q2 2023.
Essex Investment Management left its Biolase, Inc. share count unchanged in Q2 2023.
Biolase, Inc. made up ﹤0.01% of Essex Investment Management's portfolio in Q2 2023, its #420 holding.
Essex Investment Management first reported a position in Biolase, Inc. in Q3 2014 and has held it in 8 quarters since.
Essex Investment Management's Biolase, Inc. position peaked at $617K in Q4 2021.
25 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2023.

Based on Essex Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.